The related triterpenoid compounds carbenoxolone sodium (CBX) and cicloxolone sodium (CCX) have been investigated in clinical trials for treatment of herpes simplex virus (HSV) infections. When the drugs were tested in vitro, two dose-related effects on BHK cells became apparent: the rate of cell growth was reduced and the drugs exhibited cytotoxicity at high concentrations. Flow 2002 cells, in contrast, were apparently unaffected by all drug concentrations tested. The effect of up to 3 days incubation with 100 gM-CCX on BHK cells was reversible. The presence of 500 IIM-CBX or 300 gM-CCX during the HSV replication cycle reduced the infectious virus yield to less than 0.01 ~: CCX is the more potent anti-herpes agent. The contribution made by cytotoxicity to the overall antiviral effect (measured by 24 h yield) was negligible in Flow 2002 cells, and was relatively unimportant in BHK cells. The amount of HSV-1 or HSV-2 adsorbing to pretreated BHK cells was reduced by 20~ and 40~ respectively at the highest drug concentrations. Neither 500 ~tM-CBX nor 300 gM-CCX treatment for 24 h completely inhibited HSV-1 replication, but HSV-2 replication was abolished. The drugs appear to be continuously active throughout the infectious cycle. Infectious HSV particles appeared to become inactivated during or soon after egress from the cell. The two triterpenoid drugs lowered the number of virus particles made, and to a much greater extent reduced the infectious virus yield; thus, the progeny virus quality is greatly diminished. HSV-2 infections were more readily inhibited by either CCX or CBX than were HSV-1 infections.
INTRODUCTION
Placebo-controlled, double-blind clinical trials have recently established that the related triterpenoid drugs, carbenoxolone sodium (CBX) and cicloxolone sodium (CCX) have a beneficial effect in the treatment of herpes simplex virus (HSV) infections : marked reductions in both healing time and pain associated with the lesions have been reported (Poswillo & Roberts, 1981 ; Csonka & Tyrrell, 1984) . The present report initiates the investigation in vitro of the mechanism by which CCX and CBX affect the course of herpesvirus infection.
Carbenoxolone sodium B.P. is a long-established therapeutic agent for the treatment of gastric and duodenal ulcers (Johnston et al., 1974; Hossenbocus & Colin-Jones, 1974; Gheorghiu et at., 1974; Cook et al., 1980; Parke, 1983) . CBX is the synthetic hemisuccinate of the triterpenoid 18-fl-glycyrrhetic acid enoxolone, itself the aglycone of glycyrrhizic acid which is present in liquorice root (Fig. 1) . CCX is chemically similar to CBX but replacement of the succinate portion of CBX by a ring structure renders CCX more lipid-soluble. Both compounds are thus synthetic analogues of a naturally occurring plant substance. Even as disodium salts, CBX and CCX are highly lipophilic and have a strong affinity for proteins. The mechanism by which CBX promotes peptic ulcer healing is well established: a decrease in cell turnover, coupled with an increase in the synthesis of mucopolysaccharides and glycoproteins act to strengthen the mucosal barrier (Johnston et al., 1974) . We investigate here the effect of CBX and CCX on the growth of tissue culture cells, the growth of HSV-1 and HSV-2 in such cells and the effect of exposure to drugs on virus particles.
METHODS
Cell cultures. BHK-21 C13 and Vero cells were grown in Eagle's medium supplemented with 10% calf serum (EC 10). Flow 2002 human embryonic lung cells were grown in medium with 10 % foetal calf serum (EFC 10). Other media supplemented with 2% serum (EC2, EEC2) were employed as indicated.
Virus. The viruses used were HSV-I strain 17 syn +, the syncytial (syn) derivative of HSV-1 strain 17 syn (Brown et al., 1973) or HSV-2 strain HG52 (Timbury, 1971) . Plaque assays were performed as described by Brown et al. (1973) . Virus particle counts were done in a Siemens 101 electron microscope using phosphotungstic acid-stained preparations as described by Wildy et al. (1960) .
Triterpenoid drugs. CBX (mol. wt. 614.7) and CCX (tool. wt. 668.8) were the gift of Biorex Laboratories (London, U.K.) and kindly supplied to us by Miss L. Baxendale and the late Dr S. Gottfried. A 10 mM preparation of either drug was made with sterile distilled water and diluted 1 : 1 with sterile 10% bovine serum albumin (this maintains the drugs in solution). Drug preparations were freshly made for each experiment and were used immediately.
Enumeration q#total and non-viabh, cell numbers. Cells were seeded at 5 × 105 per 50 mm dish and incubated at 37 °C. After 18 h, the growth medium was replaced with EC2 or EFC2 (either drug-free, or containing 100, 300 or 500 pM-CBX, or 50, 100, 200 or 300 pM-CCX). At 0, 24, 48 and 72 h after the drug was added the cells from dishes treated in parallel were removed by two washes with 20% (v/v) trypsin/EDTA [0-25% (w/v) Difco trypsin dissolved in phosphate-buffered saline (PBS); 0.6 mM-EDTA dissolved in PBS] and resuspended in 2 ml ECI0. The medium and washes for each cell culture were pooled, subjected to low-speed centrifugation and the pellet returned to the appropriate cell suspension; then 0.1 ml was mixed with 0.1 ml of a stock trypan blue (0.5 %) or IP: 54.70.40.11
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neutral red dye (0.4~) solution prepared in PBS (170 mM-NaC1, 3-4 mM-KCI, 10 mM-Na2HPO4, 2 mM-KH2PO,). After staining for 10 rain the total and dead cell number in each sample were counted (in duplicate) using a haemocytometer. This was repeated several times, and was performed using duplicate monolayer cell cultures.
HSV adsorption curves. BHK cells (8 × 107) were suspended in 1 ml PBS, either in the absence of drug or containing CBX (500 ~M or 1 mM) or CCX (300 ~M or 600 pM). The cell suspension was incubated for 1 h at 37 °C in a shaking water-bath after which the cells were pelleted, the supernatant drawn off and the cell pellet washed with 10 ml PBS. The cells were then resuspended in 1 ml PBS containing l06 p.f.u, of HSV-1 (17 syn + or 17 syn) or HSV-2 (HG52) and incubated at 37 °C in a shaking water-bath. At 0, 15, 30 and 60 min post-infection, 0-1 ml samples of the infected cell suspension were withdrawn and mixed with 9.9 ml of ice-cold PBS. The cells were pelleted and the residual virus not adsorbed to cells was then titrated.
CBX and CCX dose-response eurves. Monolayers of BHK, Veto or Flow 2002 cells in 30 mm Petri dishes were infected with either HSV-1 or HSV-2 at a m.o.i, of 5 p.f.u./cell. After 1 h adsorption at 37 °C the cells were washed with PBS to remove unadsorbed virus and overlaid with EC2 or EFC2 containing various concentrations of CBX or CCX. Incubation at 37 °C was continued until 24 h post-adsorption when the infected cells were harvested by scraping into the growth medium. After ultrasoaic disruption of the cells, the infectious virus yields from each sample were titrated in BHK cells at 37 °C.
One-step HSV growth curves. BHK monolayers were infected with HSV-1 or HSV-2 at m.o.i. 5 p.f.u./cell as described above. After adsorption, the infected cells were overlaid with EC2 either drug-free or containing 500 ~tM-CBX or 300 ~tM-CCX. At the indicated times after adsorption, the infected cells from selected plates were harvested, disrupted by sonication and titrated as above.
Drug addition/removal BHK monolayers were infected with HSV-1 or HSV-2 at m.o.i. 5 p.f.u./cell as previously described. Addition. At various times after adsorption, CBX was added to 500 vM to the growth medium and incubation continued until 24 h post-adsorption, at which time the infected cells were harvested, disrupted and titrated as before.
Removal. After the adsorption period (1 h at 37 °C), EC2 containing 500 ~tM-CBX was added to the infected monolayers. At various times, this medium was removed, the cells were washed three times with pre-warmed PBS containing 5 ~ calf serum and then overlaid with drug-free pre-warmed EC2. Incubation at 37 °C was continued until 24 h post-adsorption, when the infected monolayers were harvested and the infectious virus yield was titrated. In both drug addition and removal experiments 24 h drug-treated and drug-free controls were included.
RESULTS

Effect of CBX and CCX on uninfected tissue culture cells
To study the effect of the drugs on uninfected BHK or Flow 2002 cells, we determined, by vital staining, both the total and non-viable cell numbers from cultures maintained at 37 °C in the presence of various concentrations of CBX or CCX. Usually, cells were treated with trypan blue dye which stains only dead cells, but in some experiments a parallel set of plates was treated with neutral red, which is taken up only by living cells. The percentage of the total cell population found to be viable after l, 2 or 3 days of drug treatment is shown in Tables 1 and 2(a). Because both vital stains provided essentially the same results only the trypan blue dye results are given.
For both drugs two dose-dependent effects were discerned in BHK cells: cell growth was reduced with increasing drug concentration and secondly cytotoxicity was evident (Table 1 ). In the case of CBX, some cytotoxic effect was perceptible at concentrations greater than 300 ~tM both at 24 h and 48 h. Cytotoxicity was a greater problem with CCX : after 24 h at concentrations greater than 200 VM, only 50~ of the cells were alive and by 48 h the effect was already very marked at concentrations greater than 50 ~tM. The drug concentrations that caused pronounced cytotoxic effects varied somewhat between experiments (compare the CCX data for BHK celts in Tables 1 and 2a ). This probably reflects the physiological state of the BHK cells available at the time. In repeated experiments CCX was consistently more toxic than CBX in BHK cells (Table 1) . To check the susceptibility of cells to these drugs, two other cell lines were tested. Vero cells were found to be strongly affected (Fig. 4) while Flow 2002 cells showed hardly any cytotoxic effect even after 3 days of treatment with 300 gM-CCX (Table 2a) .
In three independent experiments, there has been no real evidence that the rate of Flow 2002 cell division is significantly affected by CCX, nor do the results suggest a cytotoxic effect at any of the CCX concentrations tested (Table 2 a (92) 96 (95) 100 30 (86) 30 (52) 200 27 (86) 20 (50) 300 20 (50) 20 (7) * Numbers are the total cell count relative to the 48 h drug-free control given parentheses indicate the percentage of viable cells in each total cell count.
as a percentage; numbers in Table 2 . Effect of increasing CCX concentrations on (a) BHK and Flow 2002 cell growth* and (b) upon subsequent recovery oJ the cells after drug removal'~ (95) 50 (96) 89 (95) 100 (86) 50 46 (96) 100 (94) (96) 37 (96) 35 (67) 300 26 (94) 35 (76) 31 (54) 0 45 (95) 57 (96) 110 (96) 100 (89) 50 46 (93) 110 (93) 122 (88) 100 61 (94) 97 (84) 89 (87) * Numbers are percentages of the total cell count relative to the 3 day drug-free control. Numbers in parentheses indicate the percentage of total cell count represented by viable cells.
t The given numbers are multipliers indicating the increase during the 5 day recovery period in total cell number, relative to the numbers observed in individual cultures after 1, 2 or 3 days CCX treatment. This provides a measure of cell replication. Numbers in parentheses indicate the percentage of the total cell count represented by viable cells.
Cell viability and replication after reversal of CCX treatment
To determine whether the effects of CCX on cells were reversible, a set of BHK and Flow 2002 cell monolayers were treated with CCX in parallel with those employed in Table 2 days; the number of live and dead cells in each culture was then determined in the usual way (Table 2b) .
BHK cells, even after 3 days of treatment, showed good recovery from CCX concentrations up to 100 ~tM, as evidenced by increasing total cell number. Three days treatment with 200 ~tM-CCX or 2 days treatment with 300 ~tM-CCX, however, prevented the cells from proliferating, even though CCX was no longer present in the medium. Examination of the proportion of viable cells in such non-proliferating cultures revealed that (except for the 3 day/300 ~tM sample) the majority of BHK cells were still alive (Table 2b) .
There was no evidence of any long-term effect on Flow 2002 cell proliferation even after 3 days incubation with 300 pM-CCX (Table 2a) . We found no evidence of any perceptible longterm effect on subsequent cell viability (Table 2b) .
HSV adsorption to pretreated cells
Both CBX and CCX are lipophilic and consequently have a high affinity for cell membranes. It was necessary to investigate whether this property of the triterpenoid compounds interferes with the normal binding of HSV to virus receptors on the plasma membranes of drug pretreated cells. BHK cells were pretreated with CBX or CCX as described in Methods and the percentages of HSV-2 (HG52) and HSV-1 (17 syn + and 17 syn) adsorbed to these cells or controls were determined (Fig. 2) .
The particle/p.f.u, ratios of the HG52, 17 syn + and 17 syn virus stocks used in this experiment were 104, 290 and 102 respectively. Clearly, at the concentrations of CBX and CCX used there was detectable inhibition of HSV adsorption to BHK cells, implying that the triterpenoid compounds either bind at receptors, or become inserted into the plasma membrane of BHK cells in such a manner as to render a proportion of the HSV receptors on the cell surface unavailable. The observation that adsorption of HSV-2 is inhibited to a greater degree than that of HSV-1 suggests either that BHK cells have fewer HSV-2 than HSV-1 receptors, or that the nature of the HSV-2 receptors makes their blocking by triterpenoid compounds more effective. Evidence that the receptors of BHK cells for HSV-1 and HSV-2 differ has recently been provided by Addison et al. (1984) . It is unlikely that the inhibition of virus adsorption to pretreated cellsper se plays any material part in limiting the spread of infection in vitro or in vivo, as even at the very high drug concentrations used in our experiments the majority of the infectious virus particles were not prevented from binding to cell surfaces.
Efficiency of HS V plating in the presence of CBX or CCX
The efficiency of plating of HSV-1 scored as microscopic plaques on BHK monolayers was consistently reduced between tenfold and 100-fold by 500 ~tM-CBX or 300 ~tM-CCX. At 48 h after adsorption, there was in addition a marked reduction in both plaque size and 'satellite plaque' formation with concentrations higher than 100 ~tM of each drug (data not shown).
CBX and CCX dose response curves
The 24 h infectious virus yields from HSV-1-and HSV-2-infected BHK monolayers maintained at 37 °C and treated with increasing concentrations of either CBX or CCX are shown in Fig. 3(a) and (b) respectively. With 500 ~tM-CBX and 300 I.tM-CCX there was a 104-to 10S-fold reduction in the infectious virus yields for all three HSV stocks tested. Even at 50 ~tM, the lowest concentration tested for either drug, a clear reduction was detected. Fig. 3 (c) shows the dose response curves obtained for HSV-2-infected BHK and Flow 2002 cells treated with CCX. Cells were simultaneously infected using the stock of virus, treated with the same preparation of CCX and the infectious virus yields were titrated in parallel using one batch of BHK indicator cells for the plaque assay. Despite the previously noted differential sensitivities of BHK and Flow 2002 cells to CCX, the virus dose response curves were virtually identical. Very similar results have been obtained from experiments in which HSV-1 (17 syn +) and three other wild-type HSV-2 strains were used (data not shown).
Throughout our experiments CCX has consistently proved to be a more potent inhibitor of HSV replication in tissue culture than CBX.
The data shown in Fig. 3(a, b) suggest that HSV-2 (HG 52) and the syncytial variant of HSV-1 (17 syn) were more sensitive to drug-induced inhibition than was the wild-type HSV-1 (17 syn+). Additional studies employing four different strains of HSV-1 (HFEM, 13, ~ and 17 syn ÷) and three different strains of HSV-2 (UW186, MS and HG52), as well as a recent isolate of HSV-2, have confirmed that HSV-2 viruses are more strongly inhibited by either drug than HSV-! viruses (data not shown).
Uncoupling of cytotoxicity of CCX jrorn its antiviral effect
To determine whether the detected cytotoxic effect on cells contributes significantly to the overall antiviral effect of the drugs, virus dose-response and uninfected cell cytotoxicity experiments were performed in parallel with the same batches of cells and the same drug preparation. The results of three such experiments performed using uninfected and HSV-1-or HSV-2-infected Vero, BHK and Flow 2002 cells treated with CCX are shown in Fig. 4 . Cell viability (histograms) was determined tbr BHK cells by trypan blue dye exclusion only and for Vero and Flow 2002 cells by both trypan blue dye exclusion and neutral red vital staining. The diagonally drawn line shows the percentage of infectious virus yield obtained from CCX-treated cells relative to that from the drug-free control.
We conclude from these experiments that in Flow 2002 cells, CCX cytotoxicity plays virtually no part in the observed antiviral effect. In these cells, cytotoxicity and the antiviral effect of CCX are completely uncoupled. However, in BHK cells cytotoxicity may enhance the observed antiviral effect obtained in some experiments. The actual magnitude of the cytotoxic effect in a particular experiment appears to be affected by the physiological condition of the BHK cell stock used. At 24 h we have never observed BHK cell viability of less than 20%, even with 300 ~tM-CCX. Thus, cytotoxicity, though it affects precise quantification, cannot invalidate the conclusions drawn from CCX experiments in which BHK cells were used. Veto cells, on the other hand, were highly sensitive to CCX and on the basis of the neutral red data (Fig. 4) , it could be concluded that toxicity was almost entirely correlated with the observed antiviral effect.
HSV replication in the presence of CBX or CCX
The differential sensitivities of HSV-1 (17 syn +) and HSV-2 (HG52) to 500 ~M-CBX or 300 ~tM-CCX were further studied by one-step growth curves in BHK cells (Fig. 5a,b, respectively) . Production of infectious HSV-1 (17 syn ÷) progeny virus took place in the presence of either drug, but the infectious virus yield/cell was very low. In contrast, HSV-2 failed to replicate in the BHK monolayers in the presence of either drug, which supports the previously noted greater sensitivity of HSV-2 infections to inhibition by these drugs (Fig. 3) . However, the drugs did not prolong HSV-1 virus eclipse, nor did they detectably affect the rate of virus growth from 4 to 12 h after adsorption (Fig. 5a) .
Thus, drug treatment does not appear to delay or extend the normal replication cycle of the virus, but does produce reduction of infectious virus yield.
Drug addition~removal
Drug addition/removal experiments were performed to investigate whether CBX affects HSV replication during a specific period in the replication cycle. CBX to 500 ~tM was either added to, or withdrawn from, the growth medium of HSV-1-or HSV-2-infected cells at various times postadsorption with control infections in the continuous presence or absence of CBX being included in these experiments. All cultures were harvested at 24 h after adsorption and the yields of infectious virus were titrated.
The results from progressively later drug addition are shown in Fig. 6(a) . They indicate a linear relationship between time of addition of the drug and the log10 yield of infectious virus. The converse experiment involves progressively later drug removal and is shown in Fig. 6(b) . The relationship observed between time of withdrawal of CBX and final infectious virus yield appears not so straightforward, but suggests that withdrawal 10 h before harvesting results in a yield loss of 0.88 loglo units for HSV-1 (17 syn), 0.73 for HSV-1 (17 syn ÷) and 1-8 for HSV-2 (HG52). This compares with 24 h yield losses of 3.00, 2.63 and 2.9 log10 units respectively. The curves obtained from drug addition/removal experiments do not indicate a specific reversible block in the HSV replication cycle, but rather suggest that the drug's presence impairs virus replication late or throughout the cycle. Pompei et al. (1979) have reported irreversible inactivation of HSV-1 by glycyrrhizic acid. They incubated HSV-1 suspensions at 37 °C for 15 rain with 8 mM-glycyrrhizic acid and obtained a 105-fold reduction in infectious virus titre. We have performed analogous experiments in which HSV-1 or HSV-2 suspended in either 500 ~M-CBX or 300 pM-CCX were incubated at either 4 °C or 37 °C for 24 h. However, the reduction in infectious virus titre attributable to the direct effect of the drugs on virus particles was typically less than tenfold (Table 3 ) and only approached 100-fold in one instance among three repeat experiments. Essentially identical results were obtained in additional experiments where, in place of stock virus, the infectious virus (17 syn +) released from cells treated with up to 300 ~tM-CCX was used. Thus, the infectious virus particles produced in the presence or absence of CCX did not differ in sensitivity to drug-induced particle inactivation.
Effect of CBX and CCX on HS V particle suspensions
Our findings indicate that a direct effect of either drug on infectious virus particles cannot, by itself, furnish the explanation for the observed dramatic effect on HSV growth in tissue culture, although it contributes in small measure to the overall antiviral effect.
Infectious HSV in cell cultures treated with CBX and CCX
Despite the consistent 103. to 105-fold reduction in infectious virus yields obtained when growth takes place in the presence of 500 ~tM-CBX or 300 pM-CCX, some infectious virus progeny are successfully produced [most frequently found with HSV-1 17 syn + (Fig. 5a) ]. This has an obvious bearing upon the efficiency of the antiviral activity of the drugs and it is important to know whether such infectious virus is cell-associated or is released. Infectious virus present in the extracellular fluid may initiate further rounds of replication in susceptible cells and contribute to the spread of infection. The growth medium (2 ml) was drawn off the infected monolayers prior to harvesting'for a 24 h virus dose response experiment, then the detached cells were pelleted and the supernatant was taken as the cell-released virus preparation. After the cell pellet had been returned to the infected monolayers, the cells were harvested by scraping into 2 ml PBS and sonicated to provide the cell-associated virus preparation. The infectious virus yields in the cell-released and cellassociated preparations were then titrated. The results obtained for HSV-1 (17 syn +) and HSV-2 (HG52) infected BHK cells treated with CBX or CCX are shown in Fig. 7(a) and (b) respectively. With either drug, the yield of infectious HSV-1 or HSV-2 decreased faster in the cell-released samples than in the cell-associated samples. This indicates that the infectious progeny virus is almost entirely cell-associated.
It follows that the infectious virus produced in the presence of CBX or CCX is either inactivated during (or shortly after) its release from the cell, or that there is a drug-induced block at the stage of virus egress. Examination of virus particle counts from cell-associated and cellreleased virus preparations should help to discriminate between these alternatives. We are investigating whether any infectious virus made in the presence of CCX or CBX exhibits drug resistance.
HSV particle/p fu. ratios Jbllowing growth in CBX or CCX
Virus particle counts were performed by electron microscopy in which either the total virus yield, or those from cell-associated or cell-released components were examined.
The data in Table 4 show that increasing drug concentrations resulted in progressive reduction in infectious virus yield (p.f.u.), a considerably smaller decrease in the total yield of both HSV-1 and HSV-2 virus particles produced, and a very substantial increase in the particle/p.f.u, ratios. Thus, the results demonstrate that the anti-herpesvirus effect of CBX and CCX operates partly by inhibiting virus particle production, but predominantly through dramatic lowering of the quality of the progeny virions which are produced. CCX appears substantially more effective than CBX in this respect.
Experiments in which the total virus yield was separated into cell-associated and cell-released components confirm the above conclusions; in addition, the data indicate that egress is not blocked as evidenced by the maintained ratio of virus particle numbers irrespective of increasing CCX concentration (Table 5 ). The cell-released particle/p.f.u, ratios increase more rapidly than those of the cell-associated virus with increasing CCX concentrations : either the virus is inactivated during or after release from the cell or, less likely, non-infectious virus particles are preferentially released from cells. The already discussed direct effect of CCX on virus particles in suspension, if it has no equivalent in the cell, could account for a large part of the observed difference. Analogous results (not shown) were obtained with CBX-treated cells infected with HSV-1 and HSV-2. 
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DISCUSSION
Recent clinical experience demonstrates that the triterpenoid compounds CBX and CCX can be of value in the management of herpes simplex virus infections in man (Poswillo & Roberts, 1981; Partridge & Poswillo, 1984; Csonka & Tyrrell, 1984) . No detailed investigation of the mechanism of this antiviral activity in vivo or in vitro has yet been published. We have begun to study the mechanism of the anti-HSV activity exerted by these compounds. This paper documents the antiviral properties of CCX and CBX and analyses their effect at various concentrations on cell growth, virus growth and on virus particle suspensions. Subsequent papers will deal with the effects of these compounds on viral DNA and protein synthesis and polypeptide processing.
Both CBX and CCX exert two dose-related effects on uninfected BHK cells; firstly the rate of cell replication is decreased, and secondly the drugs exhibit cytotoxicity. The effect on cell replication can have little bearing on our results as infection with HSV in any case abolishes further cell replication. Moreover, confluent monolayers were used throughout. Our analysis shows that cytotoxicity may contribute to a small and variable extent to the overall antiviral activity obtained in the experiments in which BHK cells have been employed (and this contribution seems to depend on the physiological status of the particular batch of cells). By screening three cell lines, a line was identified which uncouples the antiviral and cytotoxic effects of CCX. Fortunately, the Flow 2002 cell line proves to be virtually unaffected by the concentrations of CCX employed to examine the drug's antiviral activity. It is also pertinent that no toxic effects were reported in the clinical trials in man in which CBX and CCX were Inhibition of HSV by triterpenoid drugs Csonka & Tyrrell, 1984) or dissolved in water for use as a mouthwash (Poswillo & Roberts, 1981; Partridge & Poswillo, 1984) . While the Flow 2002 cell line has a clear advantage over the BHK cell line because of its greater tolerance to triterpenoid drug treatment, the BHK/HSV-1 (strain 17) and BHK/HSV-2 (strain HG52) systems have the great advantage of having been particularly well characterized. Consequently, both the BHK and Flow 2002 cell lines were used in our investigations. The cytotoxic effect of the drugs was further characterized by showing that it was reversible. With the exception of the most severe conditions tested (300 gM for 3 days), the majority of BHK cells (70 to 80%) remained viable in cultures even when, as a consequence of drug treatment, no replication was evident following a 5 day recovery period (Table 2b) . The extent to which cytotoxicity of CCX contributes to the overall antiviral activity was small in BHK cells and negligible in Flow 2002 cells (Fig. 4) and the effect of the drugs on preformed mature HSV particles is also comparatively unimportant (Table 3) .
One-step virus growth curves showed that neither 500 ~tM-CBX nor 300 gM-CCX totally blocked HSV-1 replication, whereas HSV-2 growth was absent. This finding may well have clinical implications. Infectious virus appears to become inactivated during or shortly after egress from the cell; a block on release of virus from the infected cell could be ruled out (Table 5) .
Drug addition/removal experiments disclosed that CBX does not block virus replication at a specific point in the maturation process (for example, by specifically interacting with a particular polypeptide essential for a stage in the virus growth cycle) but that maturation is affected late or throughout the period of exposure.
CBX and CCX exhibit little specificity in their antiviral activity and, like their naturally occurring relative glycyrrhizic acid, show some effect in tissue culture against a wide range of both DNA and RNA viruses (C. R. Pringle, personal communication). Some insight into the antiviral activity of the triterpenoid compounds was gained by analysis of the particle/p.f.u. ratios of virus grown in increasing drug concentrations. CCX and CBX operate, to some extent, by reducing the number of virus particles made, but their main effect is to decrease dramatically the quality of the generated population of virus particles.
In clinical trials, Csonka & TyrreJl (1984) observed that CCX was more effective than CBX in the treatment of genital herpes infections (predominantly caused by HSV-2), while Poswillo and colleagues have only reported on carbenoxolone in the management of oral herpes infection (predominantly caused by HSV-1). In the light of these reports it is of particular interest that we consistently found the HSV-2 strain HG52 to be more sensitive to both CBX and CCX than the HSV-1 strain 17 syn +. This differential HSV type-sensitivity to both drugs applies to the four different HSV-1 and the four HSV-2 strains examined. The underlying cause of the differential sensitivity is not clear, but could reflect the higher degree of cell association found generally with HSV-2; in this context, it is interesting that the syncytial variant HSV-1 strain 17 syn (whose cell association is greater than that of the wild-type HSV-1 strain 17 syn +) was also more sensitive to triterpenoid compound inhibition.
